Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder
Status:
Unknown status
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This placebo-controlled study is designed to determine the efficacy, safety, and tolerability
of vortioxetine in the treatment of adults with Major Depressive Disorder (MDD) that is
comorbid with Social Anxiety Disorder (SAD). Half of the subjects will be randomized to
receive vortioxetine and the other half will receive placebo.